SD Plasma

Modified on 2009/10/14 21:49 by admin
SD plasma is a virally inactivated, processed blood product manufactured from pooled human plasma that can serve as an alternative to fresh frozen plasma. The manufacturing process for the product includes a solvent detergent procedure that inactivates some blood-borne viruses such as the human immunodeficiency virus (HIV, the AIDS virus), hepatitis B (HBV) and hepatitis C (HCV). This procedure is similar to ones used to inactivate viruses in numerous, more extensively processed plasma-derived products, including some clotting factors used to treat hemophiliacs. Administered intravenously, SD plasma is approved for a limited number of conditions such as the treatment of various clotting disorders, a rare condition known as TTP, and bleeding related to the use of the drug warfarin (Coumadin). SD plasma was approved by the U.S. Food and Drug Administration in 1998 and was manufactured by V.I. Technologies, Inc., Watertown, Mass., with the trade name VIPLAS/SD until 2001. The company had a contract with the American Red Cross to distribute it. V.I. sold its plasma business to Precision Pharma in 2001. In 2002, a New York-based newspaper, Newsday, reported that SD plasma was linked to 16 deaths nationwide. According to the story, SD plasma may cause fatal blood clots in recipients. Deaths occurred at several hospitals, most notably in Los Angeles, Chicago and Maryland. See your doctor if you have experienced serious side effects associated with SD plasma. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Medical Procedures: Overview
  2. Blood Clots
  Name Size